Prevail InfoWorks

This inspiring article from Pfizer follows a patient named Eric through his clinical trial journey. For those looking to learn more about the clinical trial process, this is a great resource. “From the thousands of patients who volunteer each year to the scientists, clinicians, and principal investigators (PIs), each individual who contributes to a trial helps to bring about life-changing treatments and advances our knowledge of diseases.” #ClinicalTrials #Patients #Safety #Discovery https://lnkd.in/eUQEb2bn

Melinda French Gates: Championing Women, Changing the World Looking back at the transformative success of women in 2024, we wanted to highlight Melinda French Gates and her decision to leave the Bill & Melinda Gates Foundation to focus exclusively on uplifting women and families through her own philanthropic work. Through Pivotal Ventures, the company she founded in 2015, Melinda is backing efforts to promote social progress and amplify power and influence for women globally. Key areas of focus include securing financial support for women’s health, reproductive freedoms, and fostering access to leadership roles - all aimed at building a future where women thrive as changemakers and leaders. By championing these efforts, Melinda inspires women everywhere to step into their power, embrace their potential, and lead the way toward a more equitable and inclusive world. Melinda highlighted that only 2% of U.S. charitable donations are directed toward organizations supporting women. She emphasized that investments in women's health have the potential to make a substantial impact on the global economy. “Because I have been given this extraordinary opportunity, I am determined to do everything I can to seize it and to set an agenda that helps other women and girls set theirs, too,” says Melinda. Prevail InfoWorks’ affiliate is an investment fund with a female president - always happy to see more of a focus placed on women’s health and success. Feel free to check out the article linked below. #PivotalVentures #MelindaFrenchGates #WomenEmpowerment #WomensRights #WomensHealth #WomenSupportingWomen #WomenInLeadership #Philanthropy #GenderEquality #Changemakers #InvestInWomen #GlobalImpact #SocialProgress #InclusiveFuture 

As we close the chapter on 2024, we’re filled with gratitude for the collaborations, opportunities, and milestones that shaped this year. It’s been a time of growth, both professionally and personally, and we couldn’t have done it without the incredible people around us. From achieving some hopes and dreams to embracing new ideas, colleagues and clients, this year has been marked by powerful progress and purpose. We’ve had the privilege of working alongside exceptional talent, forming meaningful partnerships, and witnessing the power of collective effort. Looking ahead to 2025, we are inspired by the opportunities that await. With renewed energy and a clear vision, we’re ready to take on the challenges of the new year and continue striving toward impactful goals. Thank you to everyone who has been a part of this journey. Your support, collaboration, and trust mean the world to us. Wishing you and your loved ones a joyful holiday season and a New Year filled with success, health, and happiness. Here’s to an exciting year ahead! Jack Houriet – CEO, Prevail InfoWorks

Wishing You all the best for a Healthy, Happy Holiday Season As we celebrate the warmth and light of this special time of year, we want to extend our heartfelt wishes to everyone enjoying the holiday season. This time reminds us of the importance of connection, congeniality, and giving hopes—values that resonate deeply in every part of our lives. Through our mission to be flexible and responsive, at Prevail InfoWorks, we are proud to support life sciences companies in their mission to bring hope and healing. Thank you to our clients, partners, and colleagues for your trust and for being part of our shared mission to make a difference in the world. Here’s to a bright and hopeful year ahead. Happy Holidays from all of us at Prevail InfoWorks! #HappyHolidays #SeasonOfJoy #PrevailInfoWorks #ClinicalTrials #InnovationInLifeSciences #BetterClinicalOutcomes #SeasonOfHope #LifeSciences #HolidayWishes #Gratitude 

Putting It All Together: Empowering Clinical Trials with Prevail InfoWorks In clinical research, success depends on the ability to see the full picture. At Prevail InfoWorks, we simplify the complexity of clinical trials by putting it all together—seamlessly aggregating and reconciling data across platforms, systems, and processes automatically. Our patented technologies and expert services enable life sciences companies to: -Streamline Data Management: Aggregate trial data from diverse sources into a single, cohesive view.  -Ensure Accuracy: Automate reconciliation processes to reduce errors and enhance oversight.  -Accelerate Outcomes: Make faster, data-driven decisions with real-time, integrated insights. By delivering unmatched data quality and operational efficiency, we give your clinical trial the best chance for success—from the start to the finish line. Discover how we can help your trials succeed learn more now: https://lnkd.in/eUmTFHrn #ClinicalTrials #DataAggregation #Innovation #PrevailInfoWorks #PrevailPartners #ClinicalDevelopment #CrossStudyCorrelation #Pharmacovigliance #FSP #FunctionalServiceProvider #ClinicalResearchOrganization #CRO 

Duo Oncology has been awarded a prestigious NIH Small Business Technology Transfer (STTR) grant to advance their innovative nanomedicine, DUO-207. This grant, provided by the National Cancer Institute (NCI), recognizes the potential of DUO-207 to transform the treatment landscape for pancreatic cancer and other challenging malignancies. Pancreatic cancer is one of the deadliest cancers, often diagnosed at late stages and leaving patients with limited treatment options. DUO-207 is designed to change that. By replacing widely used but toxic chemotherapies, this ultrasmall nanomedicine not only extends the duration of action but also significantly reduces debilitating side effects like nausea and weight loss. “This NIH STTR grant is a critical milestone in advancing DUO-207 toward clinical trials,” said Sam Rothstein, CEO of Duo Oncology. “This award validates the innovative potential of our approach to building a new foundation for cancer medicine.” Interested in learning more? Visit DuoOncology.com #PancreaticCancer #Nanomedicine #CancerInnovation #NIHGrant #OncologyBreakthroughs #CancerResearch #BiotechStartups #CancerTreatment #MedicalInnovation #FutureOfMedicine #HealthcareInnovation #Pharmaceuticals #ClinicalTrials #CancerAwareness

AbbVie Expands Innovation in Autoimmune Treatments with Nimble Therapeutics Buyout AbbVie is strengthening its autoimmune pipeline with the $200 million acquisition of Nimble Therapeutics, a Roche spinout specializing in oral peptide treatments. The deal includes milestone payments and grants AbbVie access to Nimble’s cutting-edge peptide synthesis platform. This move follows a series of strategic buyouts as AbbVie continues its push for innovative therapies. Some more details on this deal: -Pipeline Focus: Nimble’s lead IL23R inhibitor targets psoriasis and IBD, with other early-stage autoimmune candidates. -Peptide Tech: AbbVie also gains Nimble's peptide synthesis platform for drug discovery, which enables the discovery and refinement of oral peptide therapeutics. -Continued Expansion: Follows $1.4B Aliada Therapeutics and $250M Celsius Therapeutics acquisitions this year. “With AbbVie's world-class expertise in developing and commercializing medicines on a global scale, Nimble's novel oral therapies will be well-positioned to reach more people living with autoimmune diseases," says Nimble founder and CEO Jigar Patel, Ph.D. What does the acquisition of Nimble say about AbbVie’s strategy in the autoimmune space? Feel free to check out the article linked below #AbbVie #NimbleTherapeutics #AutoimmuneTherapies #PeptideTherapeutics #Innovation #DrugDiscovery #BiotechAcquisitions #OralPeptides #Psoriasis #IBD #InflammatoryBowelDisease #Biopharma #Pharmaceuticals #StrategicAcquisitions #HealthcareInnovation #PeptideSynthesis #AutoimmuneDiseases #BiotechNews #RocheSpinout #PeptideTechnology #LifeSciences #BiotechInvestment

Sustained Efficacy, Safety, and Hope: Brilaroxazine’s Impact Reviva Pharmaceuticals’ brilaroxazine is making waves in the schizophrenia treatment space following positive phase 3 trial results. The drug demonstrated sustained efficacy in reducing symptoms over a year, with a favorable safety profile and manageable side effects. As the field heats up with new contenders like Bristol Myers Squibb recently approved Cobenfy, brilaroxazine shows promise as a potential long-term solution for schizophrenia management. With so many new developments in the schizophrenia space, what excites you most about the future of treatment options? What do you think is the biggest barrier to long-term success in schizophrenia treatment—efficacy, safety, or patient adherence? “We believe these topline preliminary long-term data build on the strong clinical evidence demonstrating that brilaroxazine can improve all major symptom domains of schizophrenia, and now importantly, show sustained efficacy over time,” says Laxminarayan Bhat, Ph.D., CEO of Reviva.   Feel free to check out the article linked below #Reviva #RevivaPharmaceuticals #Brilaroxazine #Schizophrenia #SchizophreniaTreatment #MentalHealthInnovation #PharmaNews #ClinicalTrials #DrugDevelopment #PatientCare #MentalHealthMatters #Neuroscience #PharmaceuticalIndustry #HealthTech #BiotechBreakthrough #SchizophreniaAwareness #HealthcareInnovation #LongTermCare #FutureOfMedicine #Phase3

Biotech Wins Big: Atlas Venture’s New Fund and What It Means for the Industry Atlas Venture has just revealed a new and exciting $450 million fund, making it their fourteenth, to help fuel innovation in biotech. Over the past two years, the firm has launched 16 companies, recruited more than 100 executives, and played a key role in billion-dollar acquisitions by big pharma. Here are some more details on their strategy and capital: -Large Fund Secured: Atlas Venture raised a $450M biotech fund, channeled toward innovative biotech companies. -Atlas’ Major Deals: Atlas has launched 16 biotechs in the past two years with the help of their previous 2022 fund, plus $1B acquisitions by Eli Lilly and Company, GSK, and Novartis. -Focused Strategy: Backed IPOs like Disc Medicine; highlighting a disciplined, diverse approach. -Biotech Boom: Atlas joins Bain Capital Life Sciences, ARCH Venture Partners, and Forbion in recent big biotech fundraises. As excitement sparks with more money entering the industry, what could this mean for smaller sized biotechs? Which promising companies should investors keep their eye on? “Core to Atlas is a disciplined approach to our firm, funds, and portfolio,” Atlas says in a recent release. “We believe deeply in the power of a focused venture creation strategy, building biotech companies across the spectrum of disease areas, modalities, and business models.” Feel free to check out the article linked below. #AtlasVentures #Biotech #LifeSciences #VentureCapital #BiotechInnovation #HealthcareInvesting #Startups #Biopharma #BiotechFunding #PharmaDeals #FutureOfMedicine #ScienceInnovation #HealthTech #BiotechBoom #InvestInInnovation #MedicalBreakthroughs #FundingTheFuture #InnovationInHealth #BiotechStartups #PharmaInvesting #HealthCareAdvances #PrevailPartners

This Holiday Season, Maximize Your Budget for Next Year and Beyond  The clock is ticking! Don’t miss out on 10% off Prevail InfoWorks’ Single Interface™ — the industry’s leading solution to streamline your clinical trials. Integrated Analytics  Data Integration & Analytics  Clinical Systems  Clinical Adjudication  Clinical Monitoring  EDC  eConsent   CTMS  ePRO/eCOA  eTMF  Grant Navigator for Site Payments  Safety Data Management System  IRT & RTSM This exclusive end-of-year offer is the perfect opportunity to maximize your budget and finish 2024 strong. But hurry—the offer ends December 31st. Learn more and secure your discount today: https://lnkd.in/eUmTFHrn #ClinicalTrials #BudgetOptimization #CRO #FSP #DataVisualizations #Efficiencies #HolidaySavings #ClinicalDevelopment